Master Protocol Number 2.0 dated 1 Nov 2021: Part A, moderate disease: Occurrence of disease progression, defined as a progression of disease state from moderate (WHO score 4-5) to severe/critical (WHO score 6-9) or death (WHO score 10) within 14 days. Part B, severe disease: Occurrence of death within 60 days. Baricitinib specific protocol v.2.0 dated 1 Nov 2021: Occurrence of death within 60 days

Master Protocol Number 2.0 dated 1 Nov 2021: Part A, moderate disease: Occurrence of disease progression, defined as a progression of disease state from moderate (WHO score 4-5) to severe/critical (WHO score 6-9) or death (WHO score 10) within 14 days. Part B, severe disease: Occurrence of death within 60 days. Baricitinib specific protocol v.2.0 dated 1 Nov 2021: Occurrence of death within 60 days

Master Protocol Number 1.1 dated 07 April 2021: Part A, moderate disease: Occurrence of disease progression, defined as a progression of disease state from moderate (WHO score 4-5) to severe/critical (WHO score 6-9) or death (WHO score 10) within 14 days. Part B, severe disease: Occurrence of death within 60 days. Baricitinib specific protocol v. 1.1 dated 07 April 2021: Occurrence of death within 60 days

Master Protocol Number 1.1 dated 07 April 2021: Part A, moderate disease: Occurrence of disease progression, defined as a progression of disease state from moderate (WHO score 4-5) to severe/critical (WHO score 6-9) or death (WHO score 10) within 14 days. Part B, severe disease: Occurrence of death within 60 days. Baricitinib specific protocol v. 1.1 dated 07 April 2021: Occurrence of death within 60 days